吉利德科学Gilead Sciences（GILD）2025年第三季度业绩报告「NASDAQ」（英文版）（15页）.pdf

1、GILEADSCIENCESANNOUNCESTHIRDQUARTER2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$7.1billionBiktarvySalesIncreased6%Year-Over-Yearto$3.7billionFosterCity,CA,October30,2025-GileadSciences,Inc.(Nasdaq:GILD)announcedtodayitsthirdquarter2025resultsofoperations.“Wecontinuetod

2、eliveronGileadsrobustportfoliowithastrongstartforYeztugo,rapidlygrowinguptakeofBiktarvy,DescovyandLivdelzi,andpositivedataforTrodelvyin1Lmetastatictriplenegativebreastcancer,”saidDanielODay,GileadsChairmanandChiefExecutiveOfficer.“Withmultiplepotentialproductlaunchesin2026,thestrongestclinicalpipeli

3、neinGileadshistory,andnomajorlossofexclusivityexpecteduntil2036,wearewell-positionedtodrivepositiveimpactforpatientsandcontinuedgrowthofourbusiness.”ThirdQuarter2025FinancialResultsTotalthirdquarter2025revenuesincreased3%to$7.8billioncomparedtothesameperiodin2024,brokendownasfollows:Totalthirdquarte

4、r2025productsalesdecreased2%to$7.3billioncomparedtothesameperiodin2024,primarilydrivenbylowerVeklury(remdesivir)andCellTherapysales,partiallyoffsetbyhigherHIVandLivdelzi(seladelpar)sales.Totalthirdquarter2025royalty,contractandotherrevenuesincreasedbyapproximately$400millioncomparedtothesameperiodin

5、2024,primarilydrivenbyrevenuerelatedtoaprevioussaleofintellectualpropertynotexpectedtoreoccur.Dilutedearningspershare(“EPS”)was$2.43inthethirdquarter2025comparedto$1.00inthesameperiodin2024.Theincreasewasprimarilydrivenbyaprioryearpre-taxin-processresearchanddevelopment(“IPR&D”)impairmentchargeof$1.

6、75billionthatdidnotrepeatinthecurrentperiod,aswellasthe$400millionincreaseinotherrevenuementionedabove,loweracquiredIPR&Dexpensesandhighernetunrealizedgainsonequityinvestmentsinthecurrentperiod,partiallyoffsetbyhighertaxexpense.Non-GAAPdilutedEPSof$2.47inthethirdquarter2025comparedto$2.02inthesamepe